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Objectives To examine trends in the prevalence of congenital heart defects (CHDs) in Europe and to compare
these trends with the recent decrease in the prevalence of CHDs in Canada (Quebec) that was attributed to the pol-
icy of mandatory folic acid fortification.
Study design We used data for the period 1990-2007 for 47 508 cases of CHD not associated with a chromo-
somal anomaly from 29 population-based European Surveillance of Congenital Anomalies registries in 16 countries
covering 7.3 million births. We estimated trends for all CHDs combined and separately for 3 severity groups using
random-effects Poisson regression models with splines.
ResultsWe found that the total prevalence of CHDs increased during the 1990s and the early 2000s until 2004 and
decreased thereafter. We found essentially no trend in total prevalence of the most severe group (group I), whereas
the prevalence of severity group II increased until about 2000 and decreased thereafter. Trends for severity group III
(the most prevalent group) paralleled those for all CHDs combined.
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and/or voluntary fortification. However, alternative hypotheses, including
reductions in risk factors of CHDs (eg, maternal smoking) and improved
management of maternal chronic health conditions (eg, diabetes), must
also be considered for explaining the observed decrease in the preva-
lence of CHDs in Europe or elsewhere. (J Pediatr 2012;-:---).
T
he prevalence of congenital heart defects (CHDs) is known to vary across
populations and over time.1,2 These variations are at least in part due to
data issues such as completeness of the (prenatal and postnatal) diagnosis
and/or registration of cases, whether pregnancy terminations are included, which
(minor) anomalies are excluded, and the duration of ascertainment, among
other issues.
Recently, 2 reports,3,4 based on a study of trends in CHDs in Quebec, Canada,
showed an increase in the live birth prevalence of severe CHDs in the early and
middle 1990s, followed by a downward trend beginning in 1998. The authors at-
tributed this downward trend to the implementation of folic acid fortification of
food staples in Canada in 1998.
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THE JOURNAL OF PEDIATRICS  www.jpeds.com Vol.-, No.-not yet exist. Moreover, previous studies have shown that in
the past, these recommendations have not had an appreciable
effect on the prevalence of neural tube defects (NTDs) in Eu-
ropean countries.5 It is also worth noting that the currently
available evidence is much stronger for the efficacy of folic
acid for the prevention of NTDs than for the prevention of
CHDs.6,7
In Europe, most population-based congenital anomaly
registries are part of the European Surveillance of Congenital
Anomalies (EUROCAT, http://www.eurocat-network.eu/),
with a common database. Each year, EUROCAT performs
statistical monitoring for trends and clusters in time.8 In
2009, EUROCAT published a special report on CHDs,9,10
partly in response to the World Health Organization Global
Burden of Disease project. Based on some of the analyses for
this report, a general decrease in CHDs was signaled and an
additional pooled analysis of “severe” CHDs11 provided pre-
liminary evidence of a similar decrease to that in Quebec.
Given this background, and in particular given the differ-
ence between European countries and Canada in the policy
for fortification of food staples with folic acid, we thought
that it would be interesting to compare in more detail the
trends in the prevalence of CHDs in Europe with those re-
ported for Quebec. Hence, in this study, we examined trends
in total and live birth prevalence of CHDs using data for
>47 000 cases of CHD in EUROCAT registries. We estimated
the trends for both all CHD combined and separately for 3
severity groupings of CHDs.
Methods
Since 1980, the EUROCAT central database has held indi-
vidual anonymous records of cases of congenital anomaly
occurring in the registry population, including live births,
fetal deaths from 20 weeks’ gestation, and terminations of
pregnancy for fetal anomaly. Information on each of the
registries, including their methods of case ascertainment
and local procedures regarding ethics approval for the reg-
istries’ activities and their collaborations with EUROCAT,
are available elsewhere12 and on the EUROCAT Web
site (http://www.eurocat-network.eu/ABOUTUS/Member
Registries/MembersAndRegistryDescriptions/AllMembers).
All registries use the International Classification of Diseases
(ICD)-9 or -10 with British Paediatric Association extension
to code up to 9 syndrome or malformation codes for each
case.
For the current study, all cases with a code for CHD were
extracted from the EUROCAT database for the same 29
population-based registries in 16 countries that were in-
cluded in the EUROCAT CHD Special Report9 covering
nearly 7.3 million births, 1990-2007 (Table I). Only
registries with recent data (at least up to birth year 2004)
and good ascertainment based on EUROCAT data quality
indicators (>75% of EUROCAT average major congenital
anomaly prevalence and more than half the EUROCAT
average prevalence of selected severe CHDs [http://www.
eurocat-network.eu/content/DQI-Introduction-May-2008.2pdf]) were included. In practice, the participating registries
had much higher thresholds for the EUROCAT data
quality indicators than the a priori minimum values that
had been set for participation in the study.
The ICD codes defining CHDs were Q20-26 (ICD-10) and
745, 746, 7470-7474 (ICD-9-British Paediatric Association).
Minor cases of CHDs were excluded as per the EUROCAT
list of minor anomalies for exclusion (http://www.eurocat-
network.eu/content/EUROCAT-Guide-1.3.pdf), in particu-
lar patent ductus arteriosus among preterm babies. Cases
of CHD and a chromosomal anomaly were also excluded
from analysis.
We plotted the time trends, during the period 1990-2007,
in the total and live birth prevalences of all nonchromosomal
CHDs, as well as 3 severity groupings of nonchromosomal
CHDs using the EUROCAT classification of the severity of
CHDs,9 which was based on relative perinatal mortality.
These severity groupings were defined as follows: (1) severity
group I: single ventricle, hypoplastic left heart syndrome, hy-
poplastic right heart syndrome, Ebstein anomaly, tricuspid
atresia; (2) severity group II: pulmonary valve atresia, com-
mon arterial truncus, atrioventricular septal defects, aortic
valve atresia/stenosis, transposition of great vessels, tetralogy
of Fallot, total anomalous pulmonary venous return, coarcta-
tion of aorta; excluding cases with coexisting severity I CHD
anomalies; and (3) severity group III: ventricular septal de-
fect, atrial septal defect (ASD), pulmonary valve stenosis; ex-
cluding cases with coexisting severity I or severity II CHD
anomalies.
Altogether, these 3 severity groups accounted for90% of
all cases of CHD (Table I). Severity group I accounted for
7%, severity group II for 20%, and severity group III for
60% of all cases. Of the cases, 10%, including those with
patent ductus arteriosus in term infants and a few other
CHDs, were not included in any of the 3 EUROCAT
severity groups for CHDs.9
Total prevalence of CHD was defined as the total number
of cases of CHD (live births plus fetal deaths after 20 weeks of
gestation plus terminations of pregnancy for fetal anomaly)
per 10 000 total births (live births plus fetal deaths). Live birth
prevalence was defined as the number of live births with
CHD per 10 000 live births.
We examined the plots of time trends in total and live birth
prevalence of CHDs using restricted cubic splines,13-15 which
can provide a flexible, semiparametric, continuous model of
the relation between prevalence of CHD and time.
Using the number of births as the “exposure” variable, we
then used random-effects Poisson regression models to ex-
amine the annual trends in the prevalence of CHDs, for all
CHDs combined and for the 3 severity groups of CHDs.
Random-effects models were used to take into account
heterogeneity that may exist across the registries16 (http://
www.eurocat-network.eu/content/DQI-Introduction-May-
2008.pdf).
We excluded from our analyses of trends with Poisson
models cases with isolated ASDs. This was done because
the registration of the latter is likely to vary over time becauseKhoshnood et al
Table I. Study population and total prevalence of CHDs in 29 member registries in EUROCAT, 1990-2007 (see Methods












CHDs: severe I CHDs: severe II CHDs: severe III
n
Prevalence per
10 000 births n
Prevalence per
10 000 births n
Prevalence per
10 000 births
Hainaut, Belgium 1990-2007 225 381 1637 72.6 98 4.3 308 13.7 1116 49.5
Odense, Denmark 1990-2007 101 028 806 79.8 51 5.0 151 14.9 548 54.2
Paris, France 1990-2006 619 098 3954 63.9 408 6.6 917 14.8 2070 33.4
Tuscany, Italy 1990-2007 443 981 3229 72.7 168 3.8 431 9.7 2287 51.5
Dublin, Ireland 1990-2007 375 681 1682 44.8 185 4.9 561 14.9 675 18.0
Northern Netherlands 1990-2007 350 223 1956 55.9 167 4.8 540 15.4 1066 30.4
Emilia Romagna, Italy 1990-2006 471 367 2434 51.6 212 4.5 470 10.0 1459 31.0
Strasbourg, France 1990-2004 191 407 1851 96.7 114 6.0 282 14.7 1345 70.3
Vaud, Switzerland 1990-2007 135 154 1573 116.4 61 4.5 215 15.9 1067 78.9
Zagreb, Croatia 1990-2007 111 048 503 45.3 33 3.0 92 8.3 319 28.7
Malta 1990-2007 81 052 944 116.5 39 4.8 119 14.7 721 89.0
Antwerp, Belgium 1990-2007 256 747 1246 48.5 114 4.4 306 11.9 600 23.4
Basque Country, Spain 1990-2006 293 473 1218 41.5 125 4.3 390 13.3 577 19.7
Saxony-Anhalt, Germany 1990-2007 234 610 2074 88.4 110 4.7 245 10.4 1400 59.7
Mainz, Germany 1990-2006 59 403 530 89.2 48 8.1 87 14.6 348 58.6
Barcelona, Spain 1992-2006 196 160 1088 55.5 142 7.2 257 13.1 542 27.6
Styria, Austria 1990-2005 188 454 1747 92.7 104 5.5 262 13.9 1214 64.4
Cork and Kerry, Ireland 1996-2004 71 625 517 72.2 27 3.8 113 15.8 309 43.1
Sicily, Italy 1991-2004 256 935 1440 56.0 62 2.4 383 14.9 753 29.3
Wales, United Kingdom 1998-2007 323 462 3305 102.2 188 5.8 555 17.2 1987 61.4
Norway 1999-2005 406 805 3774 92.8 192 4.7 442 10.9 2322 57.1
Ukraine 2005-2007 83 446 568 68.1 37 4.4 115 13.8 346 41.5
Ile de la Reunion, France 2002-2006 73 023 391 53.5 47 6.4 82 11.2 211 28.9
Wielkopolska, Poland 1999-2006 278 536 2776 99.7 92 3.3 257 9.2 2250 80.8
Thames Valley, United Kingdom 1991-2007 169 919 493 29.0 61 3.6 185 10.9 131 7.7
Wessex, United Kingdom 1994-2007 370 122 1210 32.7 205 5.5 485 13.1 339 9.2
East Midlands and South
Yorkshire, United Kingdom
1998-2007 622 064 2139 34.4 277 4.5 606 9.7 838 13.5
Northern England 2000-2007 247 091 2149 87.0 86 3.5 506 20.5 1409 57.0
Southeast Ireland 1997-2006 61 821 274 44.3 29 4.7 61 9.9 146 23.6
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Figure 1. Time trend in total prevalence of all CHDs in 29
member registries of EUROCAT, 1990-2007. The trend was
estimated using restricted cubic splines.
- 2012 ORIGINAL ARTICLESof diagnostic or reporting issues (notably problems related to
distinguishing patent forman ovale from a true ASD). In ad-
dition, the EUROCAT instructions for coding and registra-
tion of ASDs changed recently regarding the exclusion of
patent or persistent foramen ovale (http://www.eurocat-
network.eu/content/EUROCAT-Guide-1.3.pdf) and subse-
quently a smaller number of ASD were reported by registries.
This can in turn result in a lower prevalence of CHDs, in par-
ticular for severity group III CHDs, as this group includes
isolated ASD. Hence, to avoid such bias in our trends, we ex-
cluded from the statistical analysis of trends cases with iso-
lated ASD (N = 7728).
In the Poisson models, we used different splines (or
“piece-wise exponential models”) for modeling the time
trends in the prevalence of CHDs; splines with different
knots were used to analyze the annual trends in prevalence
with (1) a single knot at 1998 to allow separate analysis of
trends (“slopes” corresponding to annual trends) before
and after 1998 in order to compare trends for EUROCAT
registries with those reported in the studies using the data
for Quebec articles3,4; (2) a single knot at 2000, as a previous
pan-European analysis of EUROCAT data had suggested
that the time trend for the total prevalence of CHDs (all
CHDs combined) changed before and after 200011; (3) 5
equal-spaced knots based on the quintiles of the distribu-Recent Decrease in the Prevalence of Congenital Heart Defects ition of the time period to allow a more detailed examina-
tion of time trends for the following periods: 1990-1993,
1994-1997, 1998-2000, 2001-2003, and 2004-2007.n Europe 3
Table III. Random-effects Poisson regression models
with splines (piece-wise exponential models) of the
trends in total and live birth prevalence of severity
groups I and II CHDs in 29 member registries in
EUROCAT, 1990-2007
Time period
Total prevalence Live birth prevalence
Annual
PR* 95% CI P†
Annual
PR* 95% CI P†
Severity group I
1990-1997 1.00 0.98-1.02 .96 0.98 0.96-1.00 <.001
1998-2007 1.00 0.99-1.01 0.97 0.95-0.99
1990-1999 1.00 0.99-1.02 .99 0.98 0.96-0.99 <.001
2000-2007 1.00 0.98-1.02 0.97 0.95-0.99
1990-1993 1.05 1.00-1.11 .44 1.04 0.99-1.10 <.001
1994-1997 0.96 0.92-1.00 0.94 0.90-0.99
1998-2000 1.02 0.97-1.07 0.97 0.92-1.03
2001-2003 0.99 0.95-1.04 0.96 0.91-1.02
2004-2007 1.01 0.95-1.06 1.01 0.94-1.09
Severity group II
1990-1997 1.05 1.03-1.06 <.001 1.05 1.04-1.06 <.001
1998-2007 0.99 0.98-0.99 0.98 0.97-0.99
1990-1999 1.04 1.03-1.05 <.001 1.04 1.03-1.05 <.001
2000-2007 0.97 0.96-0.98 0.97 0.96-0.98
1990-1993 1.03 1.00-1.07 <.001 1.04 1.00-1.08 <.001
1994-1997 1.04 1.02-1.07 1.04 1.01-1.07
1998-2000 1.01 0.98-1.04 1.00 0.97-1.04
2001-2003 0.98 0.96-1.01 0.99 0.96-1.02
2004-2007 0.95 0.92-0.99 0.94 0.90-0.97
*Annual trend in PR over the specific time period.
†P value for testing the joint statistical significance of the observed trends in the time periods.
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10; StataCorp, College Station, Texas).
Results
Figure 1 shows the time trend in the total prevalence of
CHDs for 1990-2007. The total prevalence of CHDs
increased during the 1990s and further in the early 2000s
until about 2004, and decreased thereafter. The total
prevalence of CHD was 50 per 10 000 births in 1990,
which increased to 70 per 10 000 in 2004 and decreased
to 55-60 per 10 000 at the end of the study period in 2007.
Table II shows the results of random-effects Poisson
regression models with alternative splines for modeling the
trends in the total prevalence of CHDs. These models allow
quantitative assessment of the annual trends in prevalence
during different time intervals, while taking into account
heterogeneity that may exist across the different registries.
Estimates showed that the total prevalence of CHDs (for all
CHDs combined) increased by 4% per year (annual
prevalence ratio [PR] 1.04, 95% CI, 1.02-1.06) between
1990 and 1994 with a smaller increase thereafter until 2004.
Subsequently, the total prevalence of CHDs decreased by
4% per year between 2004 and 2007 (annual PR 0.96,
95% CI, 0.95-0.98).
Figure 2 and Tables III and IV (Figure 2 and Table IV;
available at www.jpeds.com) show the time trends for the
total prevalence of CHDs for the 3 severity groupings (in
order of severity) of CHDs. In general, the trends,
including the inflection points and rates of change over
time, varied for the different severity groups. For severity
group I, the total prevalence of CHD was relatively stable at
5 per 10 000. For severity group II (Figure 2 and
Table III), the total prevalence clearly increased until about
2000 with an annual increase of 4% (annual PR 1.04, 95%
CI, 1.03-1.05) and decreased thereafter, particularly after
2004, with an annual decrease of 5% per year (annual PR
0.95, 95% CI, 0.92-0.99).Table II. Random-effects Poisson regression models
with splines (piece-wise exponential models) of the
trends in total and live birth prevalence of CHDs (all




Total prevalence Live birth prevalence
Annual
PR* 95% CI P†
Annual
PR* 95% CI P†
1990-1997 1.02 1.02-1.03 <.001 1.02 1.01-1.02 <.001
1998-2007 1.00 0.99-1.00 1.00 0.99-1.00
1990-1999 1.02 1.01-1.02 <.001 1.01 1.01-1.02 <.001
2000-2007 0.99 0.99-1.00 0.99 0.99-1.00
1990-1993 1.04 1.02-1.06 <.001 1.04 1.02-1.06 <.001
1994-1997 1.00 0.99-1.01 1.00 0.98-1.01
1998-2000 1.01 1.00-1.03 1.01 1.00-1.03
2001-2003 1.01 0.99-1.02 1.00 0.99-1.02
2004-2007 0.96 0.95-0.98 0.96 0.94-0.98
*Annual trend in PR over the specific time period.
†P value for testing the joint statistical significance of the observed trends in the time periods.
4For severity group III (Figure 2 and Table IV), the most
prevalent group, the trends were similar to those observed
for all CHD combined. The total prevalence of severity
group III CHD increased by 4% per year between 1990 and
1994 (annual PR 1.04, 95% CI, 1.02-1.06), with a small
increase thereafter until 2004. Subsequently, there was
a reversal of this trend with a decrease of 4% per year in
the total prevalence of CHD in severity group III between
2004 and 2007 (annual PR 0.96, 95% CI, 0.94-0.98).
Figure 3 (available at www.jpeds.com) and Tables III and
IV show the time trends for live birth prevalence of CHD
during the study period. In general, the trends in live birth
prevalence were similar to those noted here earlier for the
total prevalence of CHDs, except for severity group I (the
most severe group), for which the annual live birth
prevalence of CHDs decreased between 1994 and 2004 and
was essentially stable thereafter (Table III).
Discussion
Based on data on more than 47 000 case of CHD from 29
population-based registries in Europe during the period
1990 to 2007, we found that the total prevalence of CHD in-
creased on average by about 4% per year between 1990 and
2004 but decreased by about 4% per year between 2004
and 2007. These trends varied substantially across severity
groupings of CHD. Trends in the live birth prevalence of
CHDs essentially mirrored those for total prevalence of
CHD, except for the most severe group of CHD, in whichKhoshnood et al
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was stable thereafter. Given essentially no time trend in the
total prevalence for this group, this decreasing trend in the
live birth prevalence for severity group I is most likely ex-
plained by the increase in prenatal diagnosis and termination
of pregnancy for the most severe CHDs.9,10,17,18 In any case,
trends in total prevalence as noted here are likely to be the
most relevant indicator of any effects that one may attribute
to specific exposures, including any protective effects related
to folic acid.
In Quebec, Ionescu-Ittu et al3 found an increase in the live
birth prevalence of severe CHDs (a group corresponding
roughly to our severity groups I and II but including chromo-
somal syndromes) before 1998 (when fortification of food sta-
ples began in Canada) and a decrease after 1998, a decrease
that started earlier than in Europe. The authors attributed
this decrease to the implementation of the folic acid fortifica-
tion program in Canada. Subgroup analysis found that the
main decrease was in the group of severe conotruncal defects.
In our study, we found a similar increase in both the total and
live birth prevalence of nonchromosomal CHDs, excluding
patent ductus arteriosus and ASDs, in the 1990s (and early
2000s) and a decrease beginning in 2004. We found that the
decrease was in severity groups II and III (the latter was not
analyzed in Quebec). Severity group II corresponds most
closely with the severe conotruncal defects, including tetral-
ogy of Fallot, analyzed in the study by Ionescu-Ittu et al.3
The observed decrease in our data cannot be due to man-
datory fortification of food staples as such a policy has not yet
been implemented in European countries.19 Hence, alterna-
tive explanations must be considered for this decrease. One
possible explanation is an increase in folic acid intake due
to either voluntary fortification,19-21 as has been shown to
be the case in Ireland, and/or the various recommendations
issued for folic acid supplementation for women of repro-
ductive age in European countries. Nevertheless, up to
2004, these recommendations did not have an appreciable ef-
fect on the prevalence of NTDs in European countries.5 Data
on trends in folic acid intake or blood folate levels are not
currently available for Europe (other than the Irish data cited
earlier) to confirm or refute a possible role for folic acid in the
observed decrease in the prevalence of CHDs in recent years.
If the observed decrease in the prevalence of CHDs in Eu-
rope is indeed at least in part due to increases in folic acid in-
take of women, this may have occurred as a result of more
recent increases in folic acid intake that were not yet present
in the population at the time previous studies were con-
ducted. This hypothesis is consistent with the observation
that the decreasing trends in CHDs in our data were mostly
limited to the most recent period of 2004-2007. The most re-
cent analysis of NTD data in EUROCAT registries has also
pointed to a small decrease in NTDs after 2004.11,19,22
Another possibility is that the impact of folic acid on
CHDs may have a different profile in terms of the required
dose and timing of folic acid intake compared with those
of NTDs; the latter requires in particular an adequate peri-
conceptional intake of folic acid. If the intake of folic acidRecent Decrease in the Prevalence of Congenital Heart Defects iat later times (not in the periconceptional period but still suf-
ficiently early in pregnancy before or at the beginning of the
period of organogenesis) is at least somewhat more effective
for CHDs (period of organogenesis 3-8 weeks) than for
NTDs (period of organogenesis first 3 weeks), one could ob-
serve trends in CHDs as a result of increases in folic acid in-
take that may not have an appreciable impact on the
prevalence of NTDs. In particular, women may be more
likely to start taking folic acid supplements after conception
rather than preconceptionally.
Alternative hypotheses, including reductions in risk fac-
tors of CHDs (eg, maternal smoking23-25) and improved
management of maternal chronic health conditions (eg,
diabetes26,27) must also be considered for explaining the
observed decrease in the prevalence of CHDs in Europe
or elsewhere.
Registration issues or other data artifacts are unlikely to
explain the decrease in CHDs in recent years in our data.
However, an increase in prenatal and postnatal diagnoses
of CHDs may be the most plausible explanation for the in-
creases in the prevalence of CHDs observed in the 1990s in
both our data and in those from Quebec,3 although the pos-
sibility of an environmental cause, especially in relation to the
increase in severe CHDs, should not be totally discounted.
The observed differential trends in prevalence of CHDs by
severity in our data have at least 2 possible explanations. The
fact that we found no increase in CHDs for the most severe
group but a significant increase for the less severe groups in
the 1990s is likely to be at least in part explained by improve-
ments in prenatal and postnatal detection and hence more
complete registration of CHDs, particularly for the CHDs in-
cluded in severity groups II and III.
The decreases we found in the prevalence of CHDs for se-
verity groups II and III in the latter part of the study period
(2004-2007) are unlikely to be due to changes in diagnosis
and/or registration of cases. We have no reason to believe
that the diagnosis and/or registration of cases became less
complete in our data in recent years. There may have been
a small number of late diagnoses, particularly for CHDs in se-
verity group III, that were not yet registered in the 2007 data.
However, these cases would have presumably had a minor
impact on the overall EUROCAT trends during the latter
part of the study period. Moreover, the decreases we found
were not limited to 2007 data but also occurred in the prev-
alence of CHDs between 2004, 2005, and 2006. The differen-
tial trends we observed across the severity groups, particularly
the decreases observed for severity groups II and III but not
for severity group I, may be due to differential effects of folic
acid (or other etiologic factors) on different CHD anomalies,6
although this needs to be investigated further.
At this time, we cannot confirm or refute a possible role for
folic acid in the decrease in the prevalence of CHDs in Eu-
rope. Alternative hypotheses for this decrease include reduc-
tions in risk factors of CHDs (eg, maternal smoking23-25) and
improved management of maternal chronic health condi-
tions (eg, diabetes26,27). The observed decrease in the preva-
lence of CHDs is to be welcomed, but better understanding ofn Europe 5
THE JOURNAL OF PEDIATRICS  www.jpeds.com Vol.-, No.-its causes might allow public health measures to be taken to
ensure it is maximized and experienced by all sectors of the
population. n
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Table IV. Random-effects Poisson regression models
with splines (piece-wise exponential models) of the
trends in total and live birth prevalence of severity group
III CHDs in 29 member registries in EUROCAT, 1990-
2007
Time period
Total prevalence Live birth prevalence
Annual
PR* 95% CI P†
Annual
PR* 95% CI P†
1990-1997 1.02 1.01-1.03 <.001 1.02 1.01-1.02 <.001
1998-2007 1.00 0.99-1.01 1.00 0.99-1.01
1990-1999 1.01 1.01-1.02 <.001 1.01 1.01-1.02 <.001
2000-2007 1.00 0.99-1.00 1.00 0.99-1.00
1990-1993 1.04 1.02-1.06 <.001 1.04 1.02-1.06 <.001
1994-1997 0.99 0.98-1.01 0.99 0.98-1.01
1998-2000 1.02 1.00-1.04 1.02 1.00-1.04
2001-2003 1.01 0.99-1.03 1.02 1.00-1.03
2004-2007 0.96 0.94-0.98 0.96 0.93-0.98
*Annual trend in PR over the specific time period.
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Figure 2. Time trends in the total prevalence of CHDs in 29
member registries of EUROCAT, 1990-2007: A, severity
group I, B, severity group II, and C, severity group III. Trends
were estimated using restricted cubic splines.
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Figure 3. Time trends in the live birth prevalence of CHDs in 29 member registries of EUROCAT, 1990-2007. Trends are shown
forA, overall CHDsB, severity group I,C, severity group II, andD, severity group III. Trendswere estimated using restricted cubic
splines.
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